Health Condition 1: L648- Other androgenic alopecia
Conditions
Interventions
Intervention1: Dutasteride: 1 ml of 0.01% dutasteride solution diluted with equal amount of lidocaine injected intradermally for 3 session, each 4 weeks apart
Control Intervention1: Bicalutamide: 1 ml
Sponsors
Dr Jessica Jaiswal
Eligibility
Inclusion criteria
Inclusion criteria: Patients with androgenetic alopecia, Male and Female from age 18 to age 50, Patients who don t have any history of bleeding disorder.
Exclusion criteria
Exclusion criteria: Unrealistic expectations. Pregnant women. Immunocompromised patients. Patients with bleeding disorder history. Patients with any hormone dependent tumor. Patient below the age of 18 and above age of 50. Patient with any active infection involving scalp. Patient not willing to take part in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy and safety of dutasteride mesotherapy in androgenetic alopecia. To assess the efficacy and safety of bicalutamide mesotherapy in androgenetic alopecia. To compare the efficacy and safety of dutasteride mesotherapy versus bicalutamide mesotherapy in androgenetic alopecia.Timepoint: Week 0, week 4, week 12, week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Jessica Jaiswal
Baba Raghav Das Medical College
Outcome results
None listed